spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CareEvolution joins the Decentralized Trials & Research Alliance to advance participant-focused research and unlock novel digital biomarkers

CareEvolution




November 14, 2022 12:42 PM Eastern Standard Time – ANN ARBOR, Mich.--(BUSINESS WIRE) -- CareEvolution has announced a membership with the Decentralized Trials & Research Alliance (DTRA) to collaborate in the efforts to improve global adoption and education surrounding decentralized research, participant-centric trial models, and applications for novel digital biomarkers.

“These novel biomarkers and the ability for study participants to contribute to research remotely will expand our participant demographics and deepen our collective knowledge, benefitting current and future patients across the globe. We’re excited to join this Alliance and collaborate to strengthen and grow decentralized research.”

CareEvolution is a health technology company with an over 20-year legacy in data, and their platform known as HIEBus™ is leveraged by clients such as Elevance Health and Camden Coalition. In 2018 CareEvolution developed MyDataHelps™, a decentralized research platform that combines critical digital capabilities like eConsent and clinical outcome assessments with real-world data collection including Electronic Health Record (EHR), claims, digital biomarkers from wearable devices (e.g., FitBit, Apple Watch, Google Health, SensorKit), and more.

“We are committed to helping fix healthcare and further clinical trials and research by enabling researchers to access real-world data through digital biomarkers, combined with real-time survey responses for more complete, comprehensive data,” remarked Vik Kheterpal, founder of CareEvolution. “These novel biomarkers and the ability for study participants to contribute to research remotely will expand our participant demographics and deepen our collective knowledge, benefitting current and future patients across the globe. We’re excited to join this Alliance and collaborate to strengthen and grow decentralized research.”

CareEvolution has partnered with research teams across the country, including University of Massachusetts Chan Medical School, University of Michigan, the National Institutes of Health, and Scripps Research Digital Trials Center. These partners leverage MyDataHelps™ for projects such as the All of Us Research Program, RECOVER, PowerMom, Say Yes! COVID Test, and the electronic Framingham Heart Study, with nearly 2 million participants, over 55k EHRs connected and over 20 million kits distributed to participants across the United States.

DTRA is a non-profit organization convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.

Learn more about MyDataHelps™ at www.careevolution.com/mydatahelps.
phone 734-678-4788
web https://careevolution.com/
email 625 N Main Street Ann Arbor, MI 48104
 
Print this page
Send to a friend
   
spacer
News and Press Releases

At Pharmapack Paris, TekniPlex to Showcase Cleanroom-produced COC Films, Among Other Solutions

Wayne, PA – At Pharmapack Paris, February 1-2, TekniPlex, a globally integrated provider of innovative solutions through materials science and manufacturing technologies, will showcase samples from a range of cyclic olefin copolymer (COC) diagnostics films whose cleanroom production is a differentiator in the healthcare space. At booth B96-98, the company also will highlight another recently introduced innovation: the world’s first fully transparent recyclable mid-barrier blister package.
More info >>


White Papers

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

Entegris

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement